Ninth Canadian Jurisdiction Implements Biosimilar Switching Policy
Newfoundland And Labrador Will Transition Patients To Biosimilars By The End Of March 2024
Newfoundland and Labrador has become the ninth jurisdiction in Canada to implement a biosimilar switching policy for patients enrolled on its public health program.
You may also be interested in...
Ontario has joined several other Canadian provinces and territories by implementing a biosimilar switching policy for Ontarians taking biologic drugs.
Biosimilars Canada has renewed its call for Ontario to adopt a biosimilar switching policy in line with other Canadian provinces and territories, suggesting that Ontario alone could save CAD147m annually through such a scheme.
While it currently sits in fourth place, Amneal’s co-CEO Chirag Patel has laid out ambitions for the firm to become the number one supplier of affordable medicines in the US.